What is the ICD-10 code for stage IV metastatic left breast cancer with liver and lung metastases?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10 Coding for Stage IV Metastatic Left Breast Cancer with Liver and Lung Metastases

For stage IV metastatic left breast cancer with liver and lung metastases, you need to use a combination of codes: C50.912 (malignant neoplasm of left breast, female) as the primary diagnosis, followed by C78.7 (secondary malignant neoplasm of liver and intrahepatic bile duct) and C78.00 (secondary malignant neoplasm of unspecified lung) to document the metastatic sites.

Primary Breast Cancer Code

The primary malignancy code depends on the specific quadrant or location within the left breast:

  • C50.912 - Malignant neoplasm of unspecified site of left female breast (if specific location unknown)
  • C50.011 - Malignant neoplasm of nipple and areola, left female breast
  • C50.111 - Malignant neoplasm of central portion of left female breast
  • C50.211 - Malignant neoplasm of upper-inner quadrant of left female breast
  • C50.311 - Malignant neoplasm of lower-inner quadrant of left female breast
  • C50.411 - Malignant neoplasm of upper-outer quadrant of left female breast
  • C50.511 - Malignant neoplasm of lower-outer quadrant of left female breast
  • C50.811 - Malignant neoplasm of overlapping sites of left female breast

Metastatic Site Codes

Required secondary codes to document distant metastases:

  • C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
  • C78.00 - Secondary malignant neoplasm of unspecified lung (or C78.01 for right lung, C78.02 for left lung if laterality is documented)

Clinical Staging Context

While ICD-10 codes document the anatomic sites of disease, they do not explicitly capture TNM staging 1. The presence of distant metastases (M1 category) automatically classifies this as Stage IV disease regardless of primary tumor size or nodal involvement. The most common metastatic sites for breast cancer are skeleton, liver, lung, and brain, with liver and lung being particularly common in visceral metastatic disease 1.

Important Coding Considerations

Common pitfalls to avoid:

  • Do not use C54.x codes (uterine/endometrial cancer codes) - these are completely unrelated to breast cancer 2, 3
  • Always code the primary breast cancer site first, followed by the metastatic sites
  • The metastatic codes (C78.x) indicate secondary malignancy and should never be used as the principal diagnosis
  • If specific lung laterality is known, use C78.01 (right) or C78.02 (left) instead of C78.00

Documentation requirements:

The diagnosis should be supported by histological or cytological confirmation from either the primary breast tumor or metastatic sites 2. Imaging findings alone may be insufficient for definitive coding, particularly when distinguishing breast cancer liver metastases from primary intrahepatic cholangiocarcinoma 2.

Sequence of Codes

List codes in this order on claims:

  1. Primary breast cancer code (C50.xxx)
  2. Liver metastasis (C78.7)
  3. Lung metastasis (C78.00, C78.01, or C78.02)
  4. Any additional relevant codes for complications or receptor status if documented

This coding approach accurately captures the stage IV metastatic disease burden and ensures proper classification for treatment planning, prognosis assessment, and administrative purposes 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.